1. Home
  2. ONB vs ABVX Comparison

ONB vs ABVX Comparison

Compare ONB & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ONB

Old National Bancorp

N/A

Current Price

$25.49

Market Cap

9.4B

Sector

Finance

ML Signal

N/A

Logo Abivax SA American

ABVX

Abivax SA American

N/A

Current Price

$87.73

Market Cap

7.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ONB
ABVX
Founded
1834
2013
Country
United States
France
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
9.4B
7.7B
IPO Year
2012
2022

Fundamental Metrics

Financial Performance
Metric
ONB
ABVX
Price
$25.49
$87.73
Analyst Decision
Buy
Strong Buy
Analyst Count
15
12
Target Price
$28.90
★ $163.58
AVG Volume (30 Days)
★ 4.8M
852.6K
Earning Date
10-21-2026
09-21-2026
Dividend Yield
★ 2.33%
N/A
EPS Growth
★ 6.55
N/A
EPS
★ 1.90
N/A
Revenue
★ $125,616,000.00
N/A
Revenue This Year
$12.81
N/A
Revenue Next Year
$4.92
$1,695.54
P/E Ratio
$13.10
★ N/A
Revenue Growth
★ 6.07
N/A
52 Week Low
$19.60
$69.81
52 Week High
$27.36
$148.83

Technical Indicators

Market Signals
Indicator
ONB
ABVX
Relative Strength Index (RSI) 54.11 45.43
Support Level $25.40 $83.83
Resistance Level $25.80 $97.99
Average True Range (ATR) 0.63 3.75
MACD 0.05 0.51
Stochastic Oscillator 52.71 31.39

Price Performance

Historical Comparison
ONB
ABVX

About ONB Old National Bancorp

Old National Bancorp is a provider of lending and deposit services. The bank offers comprehensive wealth management, trust, investment advisory, brokerage, and foreign currency services. For businesses, it provides treasury management, merchant, and capital markets services as well as community development lending and equity investment solutions intended to produce jobs and revitalize its communities. It earns interest income on loans as well as fee income from the origination of loans and from providing other services to its clients.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: